Predicting the development of complications in patients with rhinosinusitis by cytokine profile indicators

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To develop a method for predicting the development of complications in rhinosinusitis patients based on the cytokine profile study.

Methods. We examined 110 patients with rhinosinusitis and 30 healthy donors (control group). The patients were divided into the group without a complicated course of rhinosinusitis (first group, n=65) and the group with a complicated course of rhinosinusitis (second group, n=45). The blood serum levels of interleukin (IL)-1β, IL-4, IL-8, IL-10, IL-17, IL-18, interferon (IFN)-γ were determined by enzyme immunoassay. Statistical analysis of the results was performed by using Microsoft Excel 2013 and Statistica 12.0 software. Statistically significant differences between the compared groups were determined by using the Mann–Whitney U-test, and p <0.05 was considered significant. Multivariate analysis included correlation analysis and stepwise regression analysis. The mathematical model consistency was determined by using Fisher's F-test, and p <0.05 was considered significant.

Results. Changes in cytokine profile manifested by a decrease in the level of interleukin-1β (p=0.00001), interleukin-4 (p=0.045) and an increase in the level of interleukin-18 (p=0.00001) were revealed in patients with uncomplicated course of rhinosinusitis. The complicated course of rhinosinusitis was characterized by a decrease in the level of interleukin-1β (p=0.00002), interleukin-4 (p=0.049) and an increase in the level of interleukin-8 (p=0.023), interleukin-17 (p=0.00015) and interleukin-18 (p=0.0002). Comparative analysis of the first and the second groups of patients showed an increased level of interleukin-8 (p=0.00001), interleukin-17 (p=0.0001) and reduced levels of interleukin-18 (p=0.00045) in the group of patients with complicated course of rhinosinusitis. Based on interleukin-17, interleukin-8 and interleukin-18 levels, the mathematical model for predicting the development of complications in patients with rhinosinusitis was developed.

Conclusion. The complicated course of rhinosinusitis was characterized by decreased levels of interleukin-1β, interleukin-4 and increased levels of interleukin-17, interleukin-8 and interleukin-18, indicating a more pronounced inflammatory process; for personalized therapy, an approach based on interleukin-17, interleukin-8 and interleukin-18 levels was developed on which the development of a complicated course in patients with rhinosinusitis can be predicted.

Full Text

Restricted Access

About the authors

N I Baranova

Penza Institute for Further Training of Physicians — Branch of the Russian Medical Academy of Continuous Professional Education

Email: pushino2008@yandex.ru
Russian Federation, Penza, Russia

L A Aschina

Penza Institute for Further Training of Physicians — Branch of the Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: pushino2008@yandex.ru
Russian Federation, Penza, Russia

A V Fedin

Penza Institute for Further Training of Physicians — Branch of the Russian Medical Academy of Continuous Professional Education; Clinical Hospital No. 6 named after G.А. Zakharyin

Email: pushino2008@yandex.ru
Russian Federation, Penza, Russia; Penza, Russia

N A Shkurova

Penza Institute for Further Training of Physicians — Branch of the Russian Medical Academy of Continuous Professional Education; Clinical Hospital No. 6 named after G.А. Zakharyin

Email: pushino2008@yandex.ru
Russian Federation, Penza, Russia; Penza, Russia

S V Sergeev

Penza Institute for Further Training of Physicians — Branch of the Russian Medical Academy of Continuous Professional Education

Email: pushino2008@yandex.ru
Russian Federation, Penza, Russia

References

  1. Volkov A.G., Stagnieva I.V., Eroshenko A.Iu. Significance of local pain syndrome in patients with frontitis. Vestnik otorinolaringologii. 2010; (4): 38–40. (In Russ.)
  2. Lopatin A.S., Gamov V.P. Ostryy i khronicheskiy rinosinusit: etiologiya, patogenez, klinika, diagnostika i printsipy lecheniya. (Acute and chro­nic rhinosinusitis: etiology, pathogenesis, clinical picture, diagnosis and treatment principles.) M.: Pervyy MGMU im. I.M. Sechenova, 2013; 91 р. (In Russ.)
  3. Svistushkin V.M, Shevchik E.A. Topical antibacterial therapy in the practice of otolaryngologist. Meditsinskiy sovet. 2019; (8): 10–17. (In Russ.) doi: 10.21518/2079-701X-2019-8-10-17.
  4. Eremeyeva K.V., Budeikina L.S. Speci­fics of the local treatment of acute otitis media. Meditsinskiy sovet. 2017; (8): 84–86. (In Russ.) doi: 10.21518/2079-701X-2017-8-84-86.
  5. Kryukov A.I., Kunelskaya N.L., Ivoylov A.Yu., Garov E.V., Garova E.E., Yanovskiy V.V. New trends in the treatment of uncomplicated acute otitis media in adults: evidence-based approach. Meditsinskiy sovet. 2013; (7): 36–40. (In Russ.) doi: 10.21518/2079-701X-2013-7-36-40.
  6. Bayke E.V., Urazova O.I. The cytokine profile of blood in dependence on polymorphism of cytokine genes in patients with chro­nic purulent otitis media. Bulletin of Siberian Medicine. 2018; 17 (1): 24–35. (In Russ.) doi: 10.20538/1682-0363-2018-1-24-35.
  7. Baranova N.I., Shkurova N.A., Fedin A.V. Features of the microbial picture, the activity of the phagocytosis system and the profile of key cytokines in patients with rhinosinusites and otitis media caused by the type 2 diabetes. Izvestiya vysshikh uchebnykh zavedeniy. Povolzhskiy region. 2020; (2): 5–14. (In Russ.) doi: 10.21685/2072-3032-2020-2-1.
  8. Popov N.N., Gariuk G.I., Filatova I.V., Ognivenko E.V. Clinical immunological characteristics of the course of purulent maxillary sinusitis in patients with diabetes mellitus. Mezhdunarodnyy meditsinskiy zhurnal. 2007; (1): 103–107. (In Russ.)
  9. Gurov A.V. Features of antibacterial therapy of acute purulent sinu­sitis and acute purulent otitis media. Meditsinskiy sovet. 2018; (6): 78–82. (In Russ.) doi: 10.21518/2079-701X-2018-6-78-82.
  10. Stagniyeva I.V., Simbirtsev A.S. Role of cytokine profile in manifestation of pain in rhinosinusitis. Tsitokiny i vospaleniye. 2015; 14 (4): 29–34. (In Russ.)
  11. Arefieva N.A., Aznabaeva L.F., Sharipova E.R. The role of interleukin 1-beta in pathogenesis and treatment of recurrent suppurative rhinosinusitis. Vestnik otorinolaringologii. 2012; (6): 51–52. (In Russ.)
  12. Shkurova N.A., Baranova N.I. Immunological aspects of the pathogenesis of rhinosinusitis and medium otitis with diabetes mellitus type 2. Rossiyskiy immunologicheskiy zhurnal. 2014; 8 (3): 641–644. (In Russ.)
  13. Simbirtsev A.S. Tsitokiny v patogeneze i lechenii zabolevaniy cheloveka. (Cytokines in the pathogenesis and treatment of human diseases.) SPb.: Foliant. 2018; 512 р. (In Russ.)
  14. Nacharov P.V., Klyachko L.L., Yanov Yu.K. Cytokines in the pathogenesis of otitis media. Tsitokiny i vospaleniye. 2016; 15 (1): 5–11. (In Russ.)
  15. Bezrukova E.V., Simbirtsev A.S., Kondratieva E.V., Kalashnikova O.V. The study of the levels of cytokines in nasal secretions of patients with various forms of rhinosinu­sitis. Tsitokiny i vospaleniye. 2012; 11 (2): 63–67. (In Russ.)
  16. Klimov A.V., Klimov V.V., Shustova V.A., Ta­zin I.D. Soderzhaniye IL-8, IL-17, IL-22 i IFN-γ v nazal′nom sekrete detey s khronicheskim adenoiditom i retsidiviru­yushchim kariyesom. Meditsinskaya immunologiya. 2015; 17 (S): 315. (In Russ.)
  17. Khaitov R.M. Immunologiya: struktura i funktsii immunnoy sistemy. Uchebnoe posobie. (Immunology: structure and function of the immune system. Tutorial.) M.: GEOTAR-Media. 2013; 280 р. (In Russ.)
  18. Fedin A.V., Baranova N.I. Indicators of key cytokines in patients with acute bacterial rhinosinusi­tis. Mezhdunarodnyy nauchno-issledovatel'skiy zhurnal. 2013; (7-5): 78–79. (In Russ.)

Supplementary files

There are no supplementary files to display.


© 2021 Baranova N.I., Aschina L.A., Fedin A.V., Shkurova N.A., Sergeev S.V.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies